Bioneer Corporation (064550.KQ)
KRW 19520.0
(-3.84%)
KRW 19520.0
(-3.84%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 199.25 Billion KRW | 21.93% |
| 2022 | 163.41 Billion KRW | -5.08% |
| 2021 | 172.15 Billion KRW | 7.81% |
| 2020 | 159.68 Billion KRW | 943.75% |
| 2019 | 15.29 Billion KRW | 43.5% |
| 2018 | 10.66 Billion KRW | -1.35% |
| 2017 | 10.8 Billion KRW | 33.76% |
| 2016 | 8.07 Billion KRW | -22.26% |
| 2015 | 10.39 Billion KRW | 1.92% |
| 2014 | 10.19 Billion KRW | -28.87% |
| 2013 | 14.33 Billion KRW | 27.47% |
| 2012 | 11.24 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 57.79 Billion KRW | -6.95% |
| 2024 Q3 | 65.87 Billion KRW | -15.34% |
| 2024 Q1 | 62.11 Billion KRW | 41.21% |
| 2023 Q4 | 43.98 Billion KRW | -24.57% |
| 2023 Q1 | 42.45 Billion KRW | 18.97% |
| 2023 Q3 | 58.31 Billion KRW | 6.99% |
| 2023 FY | 199.25 Billion KRW | 21.93% |
| 2023 Q2 | 54.49 Billion KRW | 28.37% |
| 2022 Q3 | 40.81 Billion KRW | 2.8% |
| 2022 Q2 | 39.7 Billion KRW | -15.92% |
| 2022 FY | 163.41 Billion KRW | -5.08% |
| 2022 Q1 | 47.21 Billion KRW | 11.65% |
| 2022 Q4 | 35.68 Billion KRW | -12.56% |
| 2021 Q3 | 50.32 Billion KRW | 19.37% |
| 2021 Q2 | 42.15 Billion KRW | 14.31% |
| 2021 Q4 | 42.29 Billion KRW | -15.96% |
| 2021 FY | 172.15 Billion KRW | 7.81% |
| 2021 Q1 | 36.88 Billion KRW | -23.1% |
| 2020 Q2 | 47.23 Billion KRW | 535.5% |
| 2020 Q3 | 59.39 Billion KRW | 25.74% |
| 2020 Q4 | 47.96 Billion KRW | -19.25% |
| 2020 Q1 | 7.43 Billion KRW | 93.06% |
| 2020 FY | 159.68 Billion KRW | 943.75% |
| 2019 Q1 | 3.37 Billion KRW | -9.35% |
| 2019 FY | 15.29 Billion KRW | 43.5% |
| 2019 Q4 | 3.84 Billion KRW | -34.77% |
| 2019 Q2 | 5.77 Billion KRW | 70.94% |
| 2019 Q3 | 5.9 Billion KRW | 2.26% |
| 2018 Q4 | 3.72 Billion KRW | 22.37% |
| 2018 Q2 | 3.77 Billion KRW | 91.1% |
| 2018 Q1 | 1.97 Billion KRW | -40.24% |
| 2018 FY | 10.66 Billion KRW | -1.35% |
| 2018 Q3 | 3.04 Billion KRW | -19.36% |
| 2017 Q1 | 3.21 Billion KRW | -8.55% |
| 2017 FY | 10.8 Billion KRW | 33.76% |
| 2017 Q4 | 3.3 Billion KRW | -4.77% |
| 2017 Q2 | 3.29 Billion KRW | 2.44% |
| 2017 Q3 | 3.47 Billion KRW | 5.36% |
| 2016 FY | 8.07 Billion KRW | -22.26% |
| 2016 Q1 | 2.4 Billion KRW | -35.43% |
| 2016 Q2 | 3.2 Billion KRW | 33.42% |
| 2016 Q4 | 3.51 Billion KRW | 65.77% |
| 2016 Q3 | 2.12 Billion KRW | -33.9% |
| 2015 Q4 | 3.72 Billion KRW | 1.03% |
| 2015 Q2 | 2.62 Billion KRW | 9.88% |
| 2015 Q1 | 2.38 Billion KRW | -16.37% |
| 2015 FY | 10.39 Billion KRW | 1.92% |
| 2015 Q3 | 3.68 Billion KRW | 40.61% |
| 2014 Q3 | 2.44 Billion KRW | 7.92% |
| 2014 Q1 | 2.63 Billion KRW | -15.73% |
| 2014 FY | 10.19 Billion KRW | -28.87% |
| 2014 Q4 | 2.85 Billion KRW | 16.69% |
| 2014 Q2 | 2.26 Billion KRW | -13.88% |
| 2013 Q2 | 3.59 Billion KRW | -3.18% |
| 2013 Q4 | 3.12 Billion KRW | -20.19% |
| 2013 Q3 | 3.91 Billion KRW | 8.94% |
| 2013 Q1 | 3.7 Billion KRW | -8.47% |
| 2013 FY | 14.33 Billion KRW | 27.47% |
| 2012 FY | 11.24 Billion KRW | 0.0% |
| 2012 Q4 | 4.05 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HLB Co., Ltd. | -6.01 Billion KRW | 3413.99% |
| iNtRON Biotechnology, Inc. | 4.56 Billion KRW | -4268.748% |
| BINEX Co., Ltd. | 56.65 Billion KRW | -251.693% |
| Anterogen.Co.,Ltd. | 2.21 Billion KRW | -8901.96% |
| MEDIPOST Co., Ltd. | 40.18 Billion KRW | -395.85% |
| CrystalGenomics, Inc. | 1.45 Billion KRW | -13575.515% |
| Helixmith Co., Ltd | 2.12 Billion KRW | -9290.526% |
| Chabiotech Co.,Ltd. | 255.19 Billion KRW | 21.92% |
| Medy-Tox Inc. | 128.16 Billion KRW | -55.47% |
| Peptron, Inc. | 1.14 Billion KRW | -17369.459% |
| Amicogen, Inc. | 51.51 Billion KRW | -286.803% |
| Genexine, Inc. | 387.48 Million KRW | -51322.14% |
| HLB Therapeutics Co.,Ltd. | 6.69 Billion KRW | -2876.477% |
| LegoChem Biosciences, Inc. | 17.79 Billion KRW | -1019.568% |
| ALTEOGEN Inc. | 31.19 Billion KRW | -538.661% |
| PharmaResearch Co., Ltd. | 182.25 Billion KRW | -9.327% |
| SillaJen, Inc. | 1.45 Billion KRW | -13577.98% |
| JETEMA, Co., Ltd. | 26.58 Billion KRW | -649.579% |
| OliX Pharmaceuticals,Inc | 14.42 Billion KRW | -1281.56% |
| Genomictree Inc. | -1.03 Billion KRW | 19284.885% |
| MedPacto, Inc. | -1.83 Billion KRW | 10972.307% |
| D&D Pharmatech | 18.67 Billion KRW | -966.834% |
| EASY BIO,Inc. | 50.88 Billion KRW | -291.568% |
| GI Innovation, Inc. | 1.98 Billion KRW | -9915.616% |